Comparing EGFR tyrosine kinase inhibitor treatments in EGFR-mutated non-small cell lung cancer across Asian and non-Asian patients: a plain language summary.

Abstract excerpt

This is a summary of a review article that looked at how people from different ethnic populations respond differently to treatments for a type of lung cancer called non-small cell lung cancer (also known as NSCLC). EGFR tyrosine kinase inhibitors (often shortened to EGFR TKI treatments) are a form of treatment for NSCLC called EGFR mutation-positive NSCLC. There are currently five EGFR TKI treatments available,...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Aniline Compounds
• Share to Carcinoma, Non-Small-Cell Lung